Coccidioidomycosis Clinical Trial
Official title:
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
In this study patients will be randomized 1:2 to receive either standard of care treatment or standard of care + Sertraline 200mg/day for 2 weeks, then 400 mg/day for 50 weeks for treatment of disseminated and meningeal coccidioidomycosis.
Sertraline has been demonstrated to have in-vitro activity against coccidioides, and in-vivo activity against cryptococcal meningitis in clinical trials. Disseminated and meningeal coccidiodes infections require lifelong treatment, have poor outcomes, and new treatment options are needed. In this study the investigators will determine safety and tolerability of adjunctive sertraline (grade 4-5 adverse reactions) compared to standard coccidioidomycosis therapy alone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04208321 -
Safety and Pharmacokinetics of VT-1598
|
Phase 1 | |
| Terminated |
NCT00614666 -
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02190266 -
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
|
||
| Completed |
NCT00796809 -
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
|
N/A | |
| Completed |
NCT00423267 -
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00690092 -
A Multi-center Study of Spherule-Derived Coccidioidin
|
Phase 3 | |
| Withdrawn |
NCT04809649 -
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
|
Phase 2 | |
| Completed |
NCT03908632 -
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
|
||
| Terminated |
NCT02663674 -
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
|
Phase 4 | |
| Terminated |
NCT03618992 -
Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment
|
N/A | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 | |
| Completed |
NCT00002325 -
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
|
N/A |